Literature DB >> 27020987

Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice.

Carly Fleagle Chisholm1, Abby E Baker1, Kaitlin R Soucie1, Raul M Torres2, John F Carpenter3, Theodore W Randolph4.   

Abstract

Therapeutic protein products can cause adverse immune responses in patients. The presence of subvisible particles is a potential contributing factor to the immunogenicity of parenterally administered therapeutic protein formulations. Silicone oil microdroplets, which derive from silicone oil used as a lubricating coating on barrels of prefilled glass syringes, are often found in formulations. In this study, we investigated the potential of silicone oil microdroplets to act as adjuvants to induce an immune response in mice against a recombinant murine protein. Antibody responses in mice to subcutaneous injections of formulations of recombinant murine growth hormone (rmGH) that contained silicone oil microdroplets were measured and compared to responses to oil-free rmGH formulations. When rmGH formulations containing silicone oil microdroplets were administered once every other week, anti-rmGH antibodies were not detected. In contrast, mice exhibited a small IgG1 response against rmGH when silicone oil-containing rmGH formulations were administered daily, and an anti-rmGH IgM response was observed at later time points. Our findings showed that silicone oil microdroplets can act as an adjuvant to promote a break in immunological tolerance and induce antibody responses against a recombinant self-protein.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adjuvant effect; immune response; immunogenicity; particle size; prefilled syringes; protein aggregation; protein formulation; protein structure; silicone oil; subvisible particles

Mesh:

Substances:

Year:  2016        PMID: 27020987      PMCID: PMC4846524          DOI: 10.1016/j.xphs.2016.02.019

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  62 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

Review 2.  The path to a successful vaccine adjuvant--'the long and winding road'.

Authors:  Derek T O'Hagan; Ennio De Gregorio
Journal:  Drug Discov Today       Date:  2009-03-05       Impact factor: 7.851

3.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models.

Authors:  Amber Haynes Fradkin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

4.  IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles.

Authors:  Anil K Tyagi; Theodore W Randolph; Aichun Dong; Kevin M Maloney; Carl Hitscherich; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

5.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

Review 6.  Biopharmaceutical formulations for pre-filled delivery devices.

Authors:  Jan Jezek; Nicholas J Darton; Barry K Derham; Nikki Royle; Iain Simpson
Journal:  Expert Opin Drug Deliv       Date:  2013-03-19       Impact factor: 6.648

7.  Assessment of the antigenic response in humans to a recombinant mutant interferon beta.

Authors:  M W Konrad; A L Childs; T C Merigan; E C Borden
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

8.  Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice.

Authors:  Grzegorz Kijanka; Wim Jiskoot; Huub Schellekens; Vera Brinks
Journal:  Pharm Res       Date:  2013-01-30       Impact factor: 4.200

9.  The adjuvant effect of silicone-gel on antibody formation in rats.

Authors:  J O Naim; R J Lanzafame; C J van Oss
Journal:  Immunol Invest       Date:  1993-03       Impact factor: 3.657

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  4 in total

1.  Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

Authors:  Austin L Daniels; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2018-02-01       Impact factor: 3.534

2.  Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used.

Authors:  Minjeong Kim; Jee Taek Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-02       Impact factor: 3.117

Review 3.  Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

Authors:  William J Anderson; Natasha Ferreira Santos da Cruz; Luiz Henrique Lima; Geoffrey G Emerson; Eduardo Büchele Rodrigues; Gustavo Barreto Melo
Journal:  Int J Retina Vitreous       Date:  2021-05-07

4.  Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.

Authors:  Manmeet Khaira; Allison L Guy
Journal:  J Oncol Pharm Pract       Date:  2021-05-18       Impact factor: 1.416

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.